An Open Label Trial of the Efficacy and Safety of Chronic Administration of the Fixed Dose Combination of Telmisartan 40mg + Amlodipine 10mg or Fixed Dose Combination of Telmisartan 80mg + Amlodipine 10mg Tablets Alone or in Combination With Other Antihypertensive Medications in Patients With Hypertension.

Trial Profile

An Open Label Trial of the Efficacy and Safety of Chronic Administration of the Fixed Dose Combination of Telmisartan 40mg + Amlodipine 10mg or Fixed Dose Combination of Telmisartan 80mg + Amlodipine 10mg Tablets Alone or in Combination With Other Antihypertensive Medications in Patients With Hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Amlodipine/telmisartan (Primary) ; Antihypertensives
  • Indications Essential hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 13 Oct 2010 A Boehringer Ingelheim media release states the EMEA has approved telmisartan/amlodipine for the treatment of hypertension in adults.
    • 26 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Mar 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top